Skip to main content

Table 3 Characteristics of included prostate cancer patients with biochemical recurrence

From: Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

Parameter

All patients

Patients without bone metastases

(m0BCR)

Patients with bone metastases

(m1BCR)

n

55

48

7

Median age in years [range]

 At prostate cancer diagnosis

65 [46–78]

65 [46–78]

66 [55–76]

 At first biochemical recurrence

71 [50–87]

71 [50–86]

72 [56–87]

Initial group according to d’Amico classification

 Low risk

7 (13%)

7

0

 Intermediate risk

23 (42%)

20

3

 High risk

19 (35%)

15

4

 Unknown

6 (10%)

6

0

Initial Gleason score

  ≤ 6

13 (24%)

13

0

 7

30 (55%)

25

5

  ≥ 8

8 (15%)

8

0

 Unknown

4 (6%)

2

2

Initial International Society of Urological Pathologists (ISUP) 2014 grade group

 1

13 (24%)

13

0

 2

17 (30%)

13

4

 3

10 (18%)

10

0

 4

7 (13%)

7

0

 5

1 (2%)

1

0

 Unknown

7 (13%)

4

3

First line treatment

 Surgery (prostatectomy ± lymph node dissection)

29 (53%)

28

1

 Definitive radiation therapy ± ADT

19 (35%)

14

5

 Other local treatment options*

7 (12%)

6

1

Median time to biochemical recurrence in months [range]

89 [4–228]

92 [4–228]

87 [6–149]

Median PSA serum value at BCR imaging workup ng/ml [range]

4.7 [0.2–137]

4.1 [0.2–52]

16.5 [1.0–137]

Management of biochemical recurrence after imaging workup

 Salvage radiation therapy (prostatic lodge ± pelvic lymph nodes) ± ADT

8 (15%)

8

0

 ADT

27 (49%)

22

5

 Surveillance

9 (16%)

9

0

 Other treatment option**

11 (20%)

9

2

  1. ADT androgen deprivation therapy; *: 4 brachytherapy and 3 high-intensity focused ultrasound (HIFU); **: 1 pelvic lymph node dissection, 7 HIFU, 1 cryoablation, 1 radiation therapy of an isolated bone metastasis and 1 surgery of 2 lung metastasis